Microbot Medical (FRA:CY9D) Moat Score: 4/10 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CY9D Microbot Medical Inc FRA:CY9D
38 GF Score
Price €1.61
! 2 Warning Signs
View Full Analysis

What is Microbot Medical Moat Score?

Microbot Medical FRA:CY9D -0.31% 38 Moat Score is 4 as of Jul. 16, 2026. GuruFocus rates FRA:CY9D with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Microbot Medical ranks better than 83.25% on this metric.

Microbot Medical has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Microbot Medical has Narrow Moat: Microbot Medical Inc has some valuable intellectual property and patents in the medical device sector. However, its market share is modest, and it faces competition from larger players. The company has potential for innovation but lacks strong brand strength and customer loyalty.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Microbot Medical might have Narrow Moat - Discernible but modest moat.

Microbot Medical  (FRA:CY9D) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Microbot Medical Moat Score Related Terms

FRA:CY9D vs STXS, POCI, DXR: Moat Score Comparison

For the Medical Instruments & Supplies subindustry, Microbot Medical's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Microbot Medical Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Microbot Medical's Moat Score distribution charts can be found below:

* The bar in red indicates where Microbot Medical's Moat Score falls into.


FRA:CY9D
38GF Score
Microbot Medical Inc FRA:CY9D
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Microbot Medical (FRA:CY9D) has a Moat Score of 4 as of Jul. 16, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Microbot Medical ranks #141 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 16.7%.
Is Microbot Medical's Moat Score too high?
Microbot Medical's current Moat Score is 4. Based on the distribution chart, Microbot Medical ranks #141 out of 842 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Microbot Medical has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Microbot Medical's Moat Score compare to STXS and POCI?
According to the Medical Devices & Instruments industry distribution chart, Microbot Medical ranks #141 out of 842 companies for Moat Score. This places Microbot Medical in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Microbot Medical's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbot Medical stock overvalued right now?
Microbot Medical (FRA:CY9D) has a current Moat Score of 4. The current Moat Score is 4. Microbot Medical's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Microbot Medical (FRA:CY9D), the current Moat Score is 4 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microbot Medical Business Description

Other Exchanges MBOT:USA
Address 175 Derby Street, Building 27, Hingham, MA, USA, 02043
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
38GF Score

Get the complete analysis for FRA:CY9D

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.61
Price